PSPatricia Senet

Patricia Senet

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Patricia Senet has a total of 111 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Management of erythromelalgia: A retrospective multicenter study

    by J.-B. Monfort, I. Lazareth, S. Blaise, G. Chaby, C. Lok, P. Senet

  • Genetic landscape of non‐ UV ‐induced cutaneous squamous cell carcinomas

    by Carmen Al Youssef, Mansour Alkobtawi, Rémi Safi, Johan Chanal, Pierre Sohier, Stéphanie Leclerc‐Mercier, Ouidad Zehou, Nicolas Ortonne, Philippe Moguelet, Patricia Senet, et al.

    Cutaneous squamous cell carcinoma (cSCC) is the second most common skin cancer and is most often caused by cumulative UV exposure. However, cSCC may also arise independently of UV exposure, on sites of sustained skin damage like chronic ulcers, scars, Recessive Dystrophic Epidermolysis Bullosa (RDEB), and inflammatory skin diseases such as hidradenitis suppurativa (HS). Little is known about non‐UV‐induced skin carcinomas. We aimed to describe the clinical, pathological, and genetic features, of non‐UV‐induced cSCC. We collected clinical and pathologic data corresponding to 31 patients with non‐UV‐induced cSCC, including 5 cSCC on HS, 4 on chronic leg ulcers and 8 on RDEB. DNA was extracted from FFPE samples and analysed using a NGS assay targeting 523 cancer genes. A comparison was performed with published genetic data obtained in non‐UV‐induced and UV‐induced cSCC. We found that the Tumour Mutational Burden (TMB) of non‐UV‐induced cSCC was 6‐times lower than the published TMB of UV‐induced cSCC. The predominant mutational signature was a clock‐wise signature. By comparing the frequency of driver mutations, we found TP53 and NOTCH1 to be significantly less frequently mutated than in UV‐mutated cSCC. Interestingly, KMT2B (a histone methyl transferase) was mutated in 11/31 non‐UV‐induced cSCC and this proportion was significantly higher than in UV‐mutated cSCC. These mutations were high impact loss‐of‐function mutations. We found that knocking down KMT2B expression using siRNA did not affect cell proliferation of SCC‐13 and A‐431 cell lines, however, it significantly increased cell migration in vitro . Taken together, this study provides a comprehensive description of non‐UV‐induced cSCC and identifies that KMT2B is mutated and involved in non‐UV‐induced cSCC carcinogenesis. © 2025 The Pathological Society of Great Britain and Ireland.

  • Étude BRASS : évaluation de l’efficacité de la toxine botulinique dans le phénomène Raynaud secondaire à la sclérodermie systémique

    by Patricia Senet, Hervé Maillard, Elisabeth Diot, Isabelle Lazareth, Sophie Blaise, Jean-Philippe Arnault, Marc-Antoine Pistorius, Carine Boulon, Olivier Cogrel, Ursula Warzocha, et al.

  • Reply

    by Patricia Senet, Eric Vicaut, For The Brass Collaborators


  • Efficacy and Safety of Botulinum Toxin in Adults with Raynaud's Phenomenon Secondary to Systemic Sclerosis: A Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Study

    by Patricia Senet, Hervé Maillard, Elisabeth Diot, Isabelle Lazareth, Sophie Blaise, Jean‐Philippe Arnault, Marc‐Antoine Pistorius, Carine Boulon, Olivier Cogrel, Ursula Warzocha, et al.

    Objective: To determine whether a single session of botulinum toxin type A (BTA) injections into both hands more effectively decreases the frequency of systemic sclerosis–associated Raynaud's phenomenon (SSc‐RP) episodes than placebo.Methods: This multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group phase III trial in patients with SSc‐RP assessed the effect of 50‐unit BTA or placebo injections into the palms of both hands around each neurovascular bundle during 1 session in winter. The primary end point was the between‐group difference in the median change in the number of RP episodes from baseline (day 0) to 4 weeks postinjection. Values between the groups were compared with the Wilcoxon rank‐sum test.Results: The intent‐to‐treat analysis included 46 BTA‐treated patients and 44 placebo recipients. At 4 weeks after assigned treatment injections, the median number of daily RP episodes decreased comparably in the BTA and placebo groups (median change –1 episode/day [interquartile range (IQR) –1.5, 0 episodes/day] and –1 episode/day [IQR –2.5, 0 episodes/day], respectively) (P = 0.77 versus placebo). Moreover, change in Raynaud's Condition Score, quality of life assessed by Health Assessment Questionnaire disability index, and hand function assessed by shortened Disabilities of the Arm, Shoulder, and Hand (QuickDASH) and Cochin Hand Function Scale from baseline to follow‐up weeks 4, 12, and 24 did not differ significantly between groups. The BTA group experienced transient hand muscle weakness significantly more frequently (P = 0.003).Conclusion: Neither the primary nor secondary end points were reached, and our results do not support any beneficial effect of palmar BTA injections to treat SSc‐RP. image


  • A new compression system for treatment of venous leg ulcers: a prospective, single-arm, clinical trial (FREEDOM)

    by Patricia Senet, Azeddine Addala, Philippe Léger, Maxime Chahim, Julie Malloizel, Sophie Blaise, Anne Sauvadet, Olivier Tacca, Markus Stücker, Joachim Dissemond

    Objective: To evaluate the efficacy, tolerability and acceptability of a new multicomponent compression system in one bandage for the local treatment of patients with venous leg ulcers (VLUs). Method: This was an international, prospective, non-comparative, clinical trial, conducted in France and Germany. Eligible participants had a VLU with a wound area of 2–20cm2, lasting for a maximum of 24 months. For a period of 6 weeks, patients were treated with a new multicomponent compression system in one bandage which was worn day and night, providing high working pressure and moderate resting pressure (UrgoK1). Clinical assessments, wound measurement and photographs were planned at weeks 1, 2, 4 and 6. The primary endpoint was the relative wound area reduction (RWAR) after 6 weeks of treatment. Secondary endpoints included wound closure rate, oedema resolution, change in patient's health-related quality of life (HRQoL), acceptability, adherence to the compression therapy, local tolerance, and physician's overall satisfaction with the evaluated compression system. Results: A cohort of 52 patients (52% female, mean age 75.4±13.0 years) with VLUs, including oedema in 58% of cases, were recruited from 22 centres. At baseline, 42 patients had already been treated with a different compression system. VLUs had been present for 5.6±4.9 months and had a mean area of 5.7±4.3cm2. After 6 weeks of treatment, a median RWAR of 91% (interquartile range: 39.4; 100.0) was achieved. Wound closure was reported in 35% of patients. A RWAR ≥40% at week 4, predictive of wound healing at 12 weeks, was achieved in 62% of patients. At the final visit, oedema present at baseline was resolved in 57% of patients. Substantial improvements in the HRQoL of the patients were reported with a decrease of the pain/discomfort and anxiety/depression dimensions. Comfort in wearing the evaluated system was reported as ‘very good’ or ‘good’ by 79% of patients, resulting in a high patient adherence to compression therapy. Compared to previous compression systems, half of the patients reported more ease in wearing shoes, and greater satisfaction and comfort with this new system. Nine non-serious adverse events related to the device or its procedure occurred in seven patients. At the final visit, the majority of the physicians were ‘very satisfied’ or ‘satisfied’ with the new compression system overall. Conclusion: The new multicomponent compression system in one bandage has been shown to promote rapid healing of VLUs, reduce oedema, improve HRQoL and to be well tolerated and accepted. It appears to be a viable alternative to existing compression systems.